Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals has reported a strong second-quarter performance, exceeding earnings estimates and prompting an update to its full-year outlook, positioning the company for continued growth and innovation.

Regeneron Pharmaceuticals experienced a week of mixed results, with both positive developments in obesity treatment and cancer research, as well as setbacks in COPD treatment.

Regeneron Pharmaceuticals Inc’s stock plummeted after disappointing results from a key clinical trial for a COPD drug, sparking a tumultuous day for the biopharmaceutical company.

Regeneron Pharmaceuticals’ stock plummeted 12% after disappointing results from a late-stage trial of a new COPD drug, sparking concerns about the company’s future prospects.

Regeneron Pharmaceuticals’ stock price plummeted 12% after disappointing results from late-stage trials of a new COPD drug, but analysts remain optimistic about the company’s long-term potential.

Regeneron Pharmaceuticals Inc. saw its stock price decline after mixed trial results for its COPD therapy, Itepekimab, but analysts remain optimistic about the company’s long-term prospects.

Regeneron Pharmaceuticals acquires 23andMe for $256 million, aiming to advance shared goals of improving human health and wellness while prioritizing customer data privacy and security.

Regeneron Pharmaceuticals Inc. saw its stock plummet 9-10% after missing earnings expectations, driven by lower-than-expected demand for its flagship product Eylea.

Regeneron Pharmaceuticals Inc. saw its stock plummet 9-10% after missing earnings expectations, driven by lower-than-expected demand for its flagship product Eylea.

Regeneron Pharmaceuticals Inc. saw its stock plummet 10% after a disappointing earnings report, driven by lower-than-expected demand for its flagship product Eylea, which is crucial to the company’s financial health.